Abbott’s Phase II Kidney Drug Shows Promise

Abbott achieved positive results from a Phase II dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic kidney disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott achieved positive results from a Phase II dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic kidney disease. Results suggest that atrasentan, used with renin-angiotensin system (RAS) inhibitors, may reduce the presence of protein in urine for patients with type 2 diabetes. Albuminuria is the main sign of diabetic nephropathy and as kidney function decrea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters